EP2091969A4 - Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren - Google Patents
Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahrenInfo
- Publication number
- EP2091969A4 EP2091969A4 EP07812601A EP07812601A EP2091969A4 EP 2091969 A4 EP2091969 A4 EP 2091969A4 EP 07812601 A EP07812601 A EP 07812601A EP 07812601 A EP07812601 A EP 07812601A EP 2091969 A4 EP2091969 A4 EP 2091969A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptides
- inflammatory
- enhanced anti
- cytotoxic properties
- decreased cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/041791 WO2007055916A2 (en) | 2005-11-07 | 2006-10-27 | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
PCT/US2007/008396 WO2007117505A2 (en) | 2006-04-05 | 2007-04-03 | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
PCT/US2007/072771 WO2008057634A2 (en) | 2006-10-26 | 2007-07-03 | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2091969A2 EP2091969A2 (de) | 2009-08-26 |
EP2091969A4 true EP2091969A4 (de) | 2010-05-12 |
Family
ID=39367532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07812601A Ceased EP2091969A4 (de) | 2006-10-27 | 2007-07-03 | Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2091969A4 (de) |
AU (1) | AU2007317755A1 (de) |
WO (1) | WO2008057634A2 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
CN101432301B (zh) | 2006-04-05 | 2014-01-08 | 洛克菲勒大学 | 具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法 |
CN101981200A (zh) | 2008-03-27 | 2011-02-23 | 诺维信公司 | 从含木素纤维素材料产生发酵产物 |
MX2010011598A (es) | 2008-04-22 | 2010-12-15 | Univ Rockefeller | Metodos para identificar compuestos anti-inflamatorios. |
EP2233499A1 (de) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antikörperzusammensetzung mit veränderter Fab-Sialylierung |
EP2233502A1 (de) * | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung |
US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
EP2459590B1 (de) | 2009-07-30 | 2015-04-22 | F.Hoffmann-La Roche Ag | Enzymatische antikörperverarbeitung |
CN102947333A (zh) | 2010-05-07 | 2013-02-27 | 瑞士杰特贝林生物制品有限公司 | 抗体组合物 |
WO2012012590A2 (en) | 2010-07-23 | 2012-01-26 | Novozymes A/S | Processes for producing fermentation products |
EA201300418A1 (ru) | 2010-10-05 | 2013-09-30 | Ф.Хоффманн-Ля Рош Аг | Антитела к человеческому tweak и варианты их применения |
AU2011329053A1 (en) * | 2010-11-15 | 2013-06-06 | Biogen Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
EP2702077A2 (de) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen |
EP2710032B1 (de) | 2011-05-20 | 2019-12-25 | Momenta Pharmaceuticals, Inc. | Modifizierte glykoproteine |
WO2013050335A1 (en) | 2011-10-05 | 2013-04-11 | F. Hoffmann-La Roche Ag | Process for antibody g1 glycoform production |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
EP4234577A3 (de) | 2012-04-25 | 2023-10-18 | Momenta Pharmaceuticals, Inc. | Modifizierte glykoproteine |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014052360A2 (en) * | 2012-09-26 | 2014-04-03 | Momenta Pharmaceuticals, Inc. | Glycoprotein preparations |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
EP3058084A4 (de) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylierte glycoproteine |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
SG11202005654QA (en) | 2017-12-19 | 2020-07-29 | Univ Rockefeller | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039488A1 (en) * | 1995-06-06 | 1996-12-12 | Genentech, Inc. | Process for controlling sialylation of proteins produced by mammalian cell culture |
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2004058944A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
WO2005063808A1 (en) * | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
WO2007005786A2 (en) * | 2005-06-30 | 2007-01-11 | Centocor, Inc. | Methods and compositions with enhanced therapeutic activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
-
2007
- 2007-07-03 AU AU2007317755A patent/AU2007317755A1/en not_active Abandoned
- 2007-07-03 WO PCT/US2007/072771 patent/WO2008057634A2/en active Application Filing
- 2007-07-03 EP EP07812601A patent/EP2091969A4/de not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039488A1 (en) * | 1995-06-06 | 1996-12-12 | Genentech, Inc. | Process for controlling sialylation of proteins produced by mammalian cell culture |
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2004058944A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
WO2005063808A1 (en) * | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
WO2007005786A2 (en) * | 2005-06-30 | 2007-01-11 | Centocor, Inc. | Methods and compositions with enhanced therapeutic activity |
Non-Patent Citations (10)
Title |
---|
DALZIEL MARTIN ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, vol. 16, no. 12, December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080 * |
JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380, ISSN: 0006-291X * |
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075 * |
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594 * |
NIMMERJAHN FALK ET AL: "The antiinflammatory activity of IgG: the intravenous IgG paradox", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, January 2007 (2007-01-01), pages 11 - 15, XP002575137, ISSN: 0022-1007 * |
RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868 - 8876, XP002461128, ISSN: 0006-2960 * |
SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, November 2006 (2006-11-01), pages 1524 - 1534, XP005792683, ISSN: 0161-5890 * |
See also references of WO2008057634A2 * |
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED .ALPHA.-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 10, 5 April 1988 (1988-04-05), pages 4576 - 4585, XP002575136, ISSN: 0021-9258 * |
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED ALPHA-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 10, 1988, pages 4576 - 4585, XP002575136, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008057634A3 (en) | 2008-12-04 |
AU2007317755A1 (en) | 2008-05-15 |
WO2008057634A2 (en) | 2008-05-15 |
EP2091969A2 (de) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200808900B (en) | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods | |
EP2091969A4 (de) | Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren | |
ZA201004045B (en) | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods | |
IL237314A0 (en) | Modified insulin polypeptides and their uses | |
IL185563A0 (en) | Gip analog and hybrid polypeptides with selectable properties | |
ZA200810323B (en) | Fkbp-l and uses thereof | |
EP2089480A4 (de) | Antimikrobielle materialien und beschichtungen | |
IL193198A0 (en) | Long-actine polypeptides and methods of producing and administering same | |
IL194751A0 (en) | Drugs and uses | |
ZA200902161B (en) | Antiobodies and immunoconjugates and uses therefor | |
ZA200904061B (en) | Fuel composition and its use | |
SI2064327T1 (sl) | DBAIT in njegova uporaba | |
ZA201002802B (en) | Functionalised materials and uses thereof | |
HK1133552A1 (en) | Carboranylporphyrins and uses thereof | |
GB0621513D0 (en) | Novel polypeptides and uses thereof | |
SI2068909T1 (sl) | Modificirani fgf-21 polipeptidi in njihova uporaba | |
GB0607798D0 (en) | Novel polypeptides and use thereof | |
IL197920A0 (en) | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods | |
ZA200904583B (en) | Dual composition with warming and analgesic effects | |
EP1977996A4 (de) | Phosphat-metall-haltiger komplex und diesen enthaltendes dichtes material | |
EP2097085A4 (de) | Therapeutische materialien und verfahren | |
PL2032708T3 (pl) | Rekombinowane nowirabdowirusy i ich zastosowania | |
GB0701295D0 (en) | Z-stilbenes derivatives and the pharmaceutical composition thereof | |
GB0907108D0 (en) | Mutants and uses therefor | |
IL192800A0 (en) | Fgf2-binding peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090519 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RAVETCH, JEFFREY V. Inventor name: NIMMERJAHN, FALK Inventor name: KANEKO, YOSHIKATSU |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE ROCKEFELLER UNIVERSITY |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100414 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1135408 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20100719 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20130201 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1135408 Country of ref document: HK |